Skip to main content

Table 1 Clinical characteristics of this subject on admission

From: Dramatic mitigation of bone pain after phosphorus replacement therapy in a subject with FGF23-related hypophosphatemic osteomalacia

WBC

5350/μL

CK

38 U/L

Whole PTH

25.6 pg/mL

Neu

66.6%

CRP

0.08 mg/dL

PTHrP

≤1.0 pmol/L

Lym

25.9%

PBS

83 mg/dL

1,25(OH)2D3

38.9 pg/mL

Mon

5.1%

HbA1c

5.3%

25(OH)D

7 ng/mL

Eo

2.2%

LDL-chol

95 mg/dL

ACTH

27.8 pg/mL

Bas

0.2%

HDL-chol

41 mg/dL

Cortisol

6.6 μg/dL

RBC

405 × 104/μL

TG

118 mg/dL

DHEA-S

74 μg/dL

Hb

12.8/μL

TSH

0.66 μU/mL

FGF23

275 pg/mL

Ht

37.7/μL

FT4

1.05 ng/dL

Osteocalcin

7.6 ng/mL

plt

18.5 × 104/μL

IgG

931 mg/dL

Serum NTx

22.8 nmol BCE/L

TP

6.1 g/dL

IgA

141.6 mg/dL

TRACP-5b

357 mU/dL

Alb

3.8 g/dL

IgM

48.7 mg/dL

BAP

88.2 μg/L

T-bil

0.3 mg/dL

Na

141 mEq/L

ucOC

1.93 ng/mL

AST

22 U/L

K

3.9 mEq/L

Intact PINP

96.5 μg/L

ALT

17 U/L

IP

1.5 mg/dL

CEA

1.5 ng/mL

γGTP

50 U/L

Ca

8.1 mg/dL

CA19-9

7.9 U/mL

ALP

855 U/L

Corrected Ca

8.3 mg/dL

CA125

8 U/mL

LDH

166 U/L

Urinary Cre

21 mg/dL

SLX

20.0 U/mL

ChE

295 U/L

Urinary P

5.9 mg/dL

AFP

2.4 ng/mL

Crn

0.37 mg/dL

Urinary Ca

9.9 mg/dL

SCC

1.9 ng/mL

BUN

11 mg/dL

FECa

4.46%

CYFRA

1.8 ng/mL

UA

4.8 mg/dL

Tmp/GFR

1.40 mg/dL

ProGRP

45.6 pg/mL